Q-omics provides the consensus-scored LAMA5 profile across patient tissues and cancer cell-line models. LAMA5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LAMA5 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, LAMA5 protein abundance shows 33,554 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where LAMA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAMA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAMA5 survival associations across molecular data types. LAMA5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAMA5 RNA expression–survival associations across cancer types. High LAMA5 expression shows unfavorable associations in UVM, KIRC, LGG and LIHC, but favorable associations in HNSC and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LAMA5 RNA expression.
This table summarizes LAMA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LAMA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAMA5 shows higher tumor expression in HNSC, LIHC, KIRP, KIRC, CHOL and COAD. The HNSC box plot shows higher LAMA5 RNA expression in tumor versus normal tissue (log2 FC = +1.339, t-test p < 0.001).
This table shows molecular features associated with LAMA5 in patient tissues and cancer cell lines. In patient samples, LAMA5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LAMA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
